Last reviewed · How we verify
CVL006 in combination with SKB264
At a glance
| Generic name | CVL006 in combination with SKB264 |
|---|---|
| Also known as | CVL006（B006 Injection）、SKB264（Sacituzumab tirumotecan） |
| Sponsor | Convalife (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CVL006 Combination Therapy in Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CVL006 in combination with SKB264 CI brief — competitive landscape report
- CVL006 in combination with SKB264 updates RSS · CI watch RSS
- Convalife (Shanghai) Co., Ltd. portfolio CI